The FDA overruled an internal review decision and granted accelerated approval to Replimune’s melanoma therapy, Tudriqev (tudriqev, reportedly tied to the company’s Replimune platform). According to newly released agency documents, Asha Das, director of the FDA biologics center’s Office of Clinical Evaluation, stepped in after the review team rejected the application. The agency’s override highlights how senior FDA leadership is actively shaping high-stakes decisions for oncology immunotherapies where evidence thresholds can be contested. Replimune’s accelerated approval path also underscores the continued scrutiny around confirmatory data plans for first-in-class or platform-driven approaches. For sponsors, the case is a reminder that the regulatory process can pivot at the leadership level even after initial scientific assessments—changing expectations for how teams design endpoints, supporting analyses, and post-approval commitments.